PERSISTENCE AND DYNAMICITY OF SARS-COV-2 ANTIBODY RESPONSE AFTER DOUBLE DOSE OF BBV-152 AND AZD1222 VACCINES: A PROSPECTIVE, LONGITUDINAL, YEAR-LONG COHORT STUDY
Intro: Different vaccines against COVID-19 have been approved by the World Health Organization (WHO) at different stages, however, limited data is available on long-term kinetics of antibodies induced by vaccines. This study was performed to investigate the persistence and dynamicity of BBV-152 (Cov...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | International Journal of Infectious Diseases |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971223003788 |
| _version_ | 1797824564684652544 |
|---|---|
| author | D. Bhattacharya D. Parai H. Choudhary S. Pati |
| author_facet | D. Bhattacharya D. Parai H. Choudhary S. Pati |
| author_sort | D. Bhattacharya |
| collection | DOAJ |
| description | Intro: Different vaccines against COVID-19 have been approved by the World Health Organization (WHO) at different stages, however, limited data is available on long-term kinetics of antibodies induced by vaccines. This study was performed to investigate the persistence and dynamicity of BBV-152 (Covaxin)- and AZD1222 (Covishield)-induced immunoglobulin-G (IgG) antibodies over the year and neutralizing antibodies’ status after the one-month post booster dose. Methods: This 52-week longitudinal cohort study documented antibody persistence and neutralizing antibody status among 278 health-care workers (HCWs) from four different healthcare and research facilities in Odisha, enrolled in January 2021 and continued until March 2022. An automated chemiluminescence immune assay (CLIA) platform from Abbott Diagnostics was used to quantify IgG antibodies against SARS-CoV-2′s spike receptor-binding domain (RBD) and a surrogate virus neutralization test (sVNT) was performed by enzyme-linked immunosorbent assay (ELISA). If any participants developed any symptoms of COVID-19, nasopharyngeal swabs were collected and sent to ICMR- RMRC, Bhubaneswar for RT-PCR confirmation. Findings: Among the 243 participants, 119 HCWs (48.97%) were Covaxin recipients and the remaining 124 (51.02%) were Covishield recipients. During the seven follow- ups, 104 participants (42.79%) were identified as vaccine breakthrough cases. In 139 non-infected HCWs, the median antibody titer significantly waned after ten months of double dose, both for Covaxin (342.7 AU/mL at DD1 vs 43.9 AU/mL at DD10) and Covishield (2325.8 AU/mL at DD3 vs 595.2 AU/mL at DD10). No statistically significant differences in antibody titers were observed based on age, gender, comorbidities, and blood groups. The median inhibition activity of sVNT was increased significantly for Covaxin and Covishield booster recipients. Among the booster dose recipients, 24 had breakthrough cases by the Omicron variant. Conclusion: Results of this longitudinal cohort study can be used to implement vaccination strategies and could also aid in tracking and designing vaccine mandates to minimize vaccine escape. |
| first_indexed | 2024-03-13T10:40:52Z |
| format | Article |
| id | doaj.art-3e84f955c77f4f4fb3d6585f6492c6cb |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-03-13T10:40:52Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-3e84f955c77f4f4fb3d6585f6492c6cb2023-05-18T04:38:47ZengElsevierInternational Journal of Infectious Diseases1201-97122023-05-01130S100PERSISTENCE AND DYNAMICITY OF SARS-COV-2 ANTIBODY RESPONSE AFTER DOUBLE DOSE OF BBV-152 AND AZD1222 VACCINES: A PROSPECTIVE, LONGITUDINAL, YEAR-LONG COHORT STUDYD. Bhattacharya0D. Parai1H. Choudhary2S. Pati3ICMR-Regional Medical Research Centre, Bhubaneswar, Microbiology, Bhubaneswar, IndiaICMR-Regional Medical Research Centre, Bhubaneswar, Microbiology, Bhubaneswar, IndiaICMR-Regional Medical Research Centre, Bhubaneswar, Microbiology, Bhubaneswar, IndiaICMR-Regional Medical Research Centre, Bhubaneswar, Microbiology, Bhubaneswar, IndiaIntro: Different vaccines against COVID-19 have been approved by the World Health Organization (WHO) at different stages, however, limited data is available on long-term kinetics of antibodies induced by vaccines. This study was performed to investigate the persistence and dynamicity of BBV-152 (Covaxin)- and AZD1222 (Covishield)-induced immunoglobulin-G (IgG) antibodies over the year and neutralizing antibodies’ status after the one-month post booster dose. Methods: This 52-week longitudinal cohort study documented antibody persistence and neutralizing antibody status among 278 health-care workers (HCWs) from four different healthcare and research facilities in Odisha, enrolled in January 2021 and continued until March 2022. An automated chemiluminescence immune assay (CLIA) platform from Abbott Diagnostics was used to quantify IgG antibodies against SARS-CoV-2′s spike receptor-binding domain (RBD) and a surrogate virus neutralization test (sVNT) was performed by enzyme-linked immunosorbent assay (ELISA). If any participants developed any symptoms of COVID-19, nasopharyngeal swabs were collected and sent to ICMR- RMRC, Bhubaneswar for RT-PCR confirmation. Findings: Among the 243 participants, 119 HCWs (48.97%) were Covaxin recipients and the remaining 124 (51.02%) were Covishield recipients. During the seven follow- ups, 104 participants (42.79%) were identified as vaccine breakthrough cases. In 139 non-infected HCWs, the median antibody titer significantly waned after ten months of double dose, both for Covaxin (342.7 AU/mL at DD1 vs 43.9 AU/mL at DD10) and Covishield (2325.8 AU/mL at DD3 vs 595.2 AU/mL at DD10). No statistically significant differences in antibody titers were observed based on age, gender, comorbidities, and blood groups. The median inhibition activity of sVNT was increased significantly for Covaxin and Covishield booster recipients. Among the booster dose recipients, 24 had breakthrough cases by the Omicron variant. Conclusion: Results of this longitudinal cohort study can be used to implement vaccination strategies and could also aid in tracking and designing vaccine mandates to minimize vaccine escape.http://www.sciencedirect.com/science/article/pii/S1201971223003788 |
| spellingShingle | D. Bhattacharya D. Parai H. Choudhary S. Pati PERSISTENCE AND DYNAMICITY OF SARS-COV-2 ANTIBODY RESPONSE AFTER DOUBLE DOSE OF BBV-152 AND AZD1222 VACCINES: A PROSPECTIVE, LONGITUDINAL, YEAR-LONG COHORT STUDY International Journal of Infectious Diseases |
| title | PERSISTENCE AND DYNAMICITY OF SARS-COV-2 ANTIBODY RESPONSE AFTER DOUBLE DOSE OF BBV-152 AND AZD1222 VACCINES: A PROSPECTIVE, LONGITUDINAL, YEAR-LONG COHORT STUDY |
| title_full | PERSISTENCE AND DYNAMICITY OF SARS-COV-2 ANTIBODY RESPONSE AFTER DOUBLE DOSE OF BBV-152 AND AZD1222 VACCINES: A PROSPECTIVE, LONGITUDINAL, YEAR-LONG COHORT STUDY |
| title_fullStr | PERSISTENCE AND DYNAMICITY OF SARS-COV-2 ANTIBODY RESPONSE AFTER DOUBLE DOSE OF BBV-152 AND AZD1222 VACCINES: A PROSPECTIVE, LONGITUDINAL, YEAR-LONG COHORT STUDY |
| title_full_unstemmed | PERSISTENCE AND DYNAMICITY OF SARS-COV-2 ANTIBODY RESPONSE AFTER DOUBLE DOSE OF BBV-152 AND AZD1222 VACCINES: A PROSPECTIVE, LONGITUDINAL, YEAR-LONG COHORT STUDY |
| title_short | PERSISTENCE AND DYNAMICITY OF SARS-COV-2 ANTIBODY RESPONSE AFTER DOUBLE DOSE OF BBV-152 AND AZD1222 VACCINES: A PROSPECTIVE, LONGITUDINAL, YEAR-LONG COHORT STUDY |
| title_sort | persistence and dynamicity of sars cov 2 antibody response after double dose of bbv 152 and azd1222 vaccines a prospective longitudinal year long cohort study |
| url | http://www.sciencedirect.com/science/article/pii/S1201971223003788 |
| work_keys_str_mv | AT dbhattacharya persistenceanddynamicityofsarscov2antibodyresponseafterdoubledoseofbbv152andazd1222vaccinesaprospectivelongitudinalyearlongcohortstudy AT dparai persistenceanddynamicityofsarscov2antibodyresponseafterdoubledoseofbbv152andazd1222vaccinesaprospectivelongitudinalyearlongcohortstudy AT hchoudhary persistenceanddynamicityofsarscov2antibodyresponseafterdoubledoseofbbv152andazd1222vaccinesaprospectivelongitudinalyearlongcohortstudy AT spati persistenceanddynamicityofsarscov2antibodyresponseafterdoubledoseofbbv152andazd1222vaccinesaprospectivelongitudinalyearlongcohortstudy |